Geron Announces New Overall Survival Data From IMbark In Imetelstat-Treated Patients With Intermediate-2 Or High-Risk Myelofibrosis And Relapsed/Refractory To Janus Kinase Inhibitor Therapy ; Reports Median Overall Survival Of 29.9 Months In High-Dose Arm
Benzinga Newsdesk